AKT1 and cancer: Considering that miR-184 and miR-22-3p are downregulated in cancer patients, this suggests that plasma from high-risk, yet cancer-free individuals contain EV and circulating miRNAs that suppress WNT and the AKT signaling axis and that these mechanisms are restrained in NSCLC patients.